Effects of “trendy” weight loss drugs on the consumption of alcoholic beverages
Alcohol use disorder (AUD) is a major global health burden with high relapse rates and low adoption of treatment. Given the limited effectiveness and uptake of current pharmacotherapies for AUD, recent research has explored novel neurobiological ways, particularly those involved in metabolic and appetite-regulating pathways.
Weight‑loss drugs like semaglutide and tirzepatide (called glucagon-like peptide-1 receptor agonists, GLP‑1 RA) (*) are medications which help individuals lose weight by acting on the same hormones the body uses to control appetite and blood sugar. Initially, they were used to treat type 2 diabetes, and now they are also used (at higher doses) specifically for obesity. This medication makes individuals feel fuller sooner and longer, they eat smaller portions and don’t get hungry again as quickly. Thus, most individuals lose a considerable amount of weight over a few months. Because they strongly affect appetite, they have shown the potential to be a promising class of medications currently under investigation for reducing the excessive consumption of alcoholic beverages. The real-world applicability of GLP-1 RAs in reducing alcohol consumption is particularly relevant for individuals with obesity or type 2 diabetes mellitus – individuals that often have higher rates of alcohol use and face compounded health risks. The dual benefit of GLP-1 RAs in improving metabolic parameters while simultaneously reducing alcohol intake presents a unique therapeutic opportunity. As such, these agents may be especially well-suited for treating both metabolic disease and alcohol use disorder (AUD) and offer a pragmatic solution in settings where adherence to traditional AUD treatments is low and coexisting obesity and type 2 diabetes is high.
The current systematic review and meta-analysis evaluated the effects of GLP-1 RA medications on the consumption of alcoholic beverages, liver-related outcomes, and mortality. Most of the research so far is in individuals with obesity or diabetes, not in individuals who drink only small or moderate amounts and do not consume excessively. The findings of this review are broadly consistent with earlier animal and human studies suggesting that GLP-1 receptor agonists may reduce alcohol use and improve liver outcomes among high-risk individuals, although evidence remains limited and is not completely consistent. Observational studies have reported that patients taking GLP‑1 drugs were drinking less alcoholic beverages and had fewer alcohol‑related and liver‑related medical problems, and improved mortality rates, but the evidence is still early and not completely consistent. In randomized controlled trials, the results have been more variable, and sometimes dependent on body weight (BMI).
Most of the existing studies have important limitations: they often rely on participants self‑reporting how much they drink, they usually follow patients only for a relatively short time, and observational studies can be influenced by confounding factors (for example stress, diet, or social support) that are hard to fully control for. Because of this, the finding should be interpreted with caution, and the authors call for longer-term RCTs to evaluate the lasting effects of GLP1 drugs as a reliable long‑term treatment for alcohol use disorder.
(*) Common brand names: Ozempic, Wegovy, Mounjaro, etc.
